HIGH DOSE CHEMOTHERAPY AND COMBINATION ANTI-HIV THERAPY FOR HIV ASSOCIATED HO

针对 HIV 相关性 HO 的高剂量化疗和抗 HIV 联合治疗

基本信息

  • 批准号:
    7368154
  • 负责人:
  • 金额:
    $ 0.3万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-12-01 至 2006-11-30
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research study is to determine whether peripheral blood progenitor cells (immature cells that can become blood cells) can be collected from patients with HIV infection who are being treated with combination anti-HIV therapy. These cells will be given back to research participants after high dose chemotherapy for non-Hodgkin's lymphoma (NHL) or Hodgkin's Disease (HD). Additional purposes are to evaluate the side effects of this treatment and estimate the disease-free and overall survival. The prognosis of patients with HIV-related NHL/HD is very poor with conventional chemotherapy and/or radiotherapy. Although remission (absence of detectable lymphoma) can be achieved, the duration of remission usually is short. Recent studies have shown that persons who have NHL/HD but no HIV infection who receive high dose chemotherapy in an effort to destroy any remaining NHL/HD can achieve long-term remission. However, this type of intensive therapy also destroys normal marrow cells. To help reduce this problem, the patient's peripheral blood progenitor cells (PBPC) can be collected part way through chemotherapy to be returned to the subject intravenously (through a vein) after the intensive therapy is over. This procedure is called autologous PBPC transplantation.
该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者(PI)可能从另一个NIH来源获得主要资金,因此可以在其他CRISP条目中表示。所列机构为中心,不一定是研究者所在机构。本研究的目的是确定是否可以从正在接受联合抗HIV治疗的HIV感染患者中收集外周血祖细胞(可以成为血细胞的未成熟细胞)。这些细胞将在非霍奇金淋巴瘤(NHL)或霍奇金病(HD)的高剂量化疗后返还给研究参与者。其他目的是评估这种治疗的副作用,并估计无病生存期和总生存期。 常规化疗和/或放疗对HIV相关NHL/HD患者的预后非常差。虽然可以达到缓解(没有可检测到的淋巴瘤),但缓解的持续时间通常很短。最近的研究表明,患有NHL/HD但没有HIV感染的人接受大剂量化疗以破坏任何剩余的NHL/HD可以实现长期缓解。然而,这种类型的强化治疗也会破坏正常的骨髓细胞。为了帮助减少这个问题,患者的外周血祖细胞(PBPC)可以通过化疗部分收集,以便在强化治疗结束后静脉内(通过静脉)返回给受试者。这种方法被称为自体PBPC移植。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

AMRITA KRISHNAN其他文献

AMRITA KRISHNAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('AMRITA KRISHNAN', 18)}}的其他基金

A PILOT STUDY OF SAFETY AND FEASIBILITY OF STEM CELL THERAPY FOR AIDS
干细胞治疗艾滋病的安全性和可行性试点研究
  • 批准号:
    7716664
  • 财政年份:
    2008
  • 资助金额:
    $ 0.3万
  • 项目类别:
PILOT STUDY OF SAFETY AND FEASIBILITY OF STEM CELL THERAPY FOR AIDS
干细胞治疗艾滋病的安全性和可行性试点研究
  • 批准号:
    7982077
  • 财政年份:
    2008
  • 资助金额:
    $ 0.3万
  • 项目类别:
CLINICAL TRIAL: A PILOT STUDY OF YTTRIUM-90-LABELED ANTI-CD20 MONOCLONAL
临床试验:钇 90 标记的抗 CD20 单克隆抗体的试点研究
  • 批准号:
    7716636
  • 财政年份:
    2008
  • 资助金额:
    $ 0.3万
  • 项目类别:
A PILOT STUDY OF YTTRIUM-90-LABELED ANTI-CD20 MONOCLONAL
钇90标记的抗CD20单克隆抗体的初步研究
  • 批准号:
    7603867
  • 财政年份:
    2006
  • 资助金额:
    $ 0.3万
  • 项目类别:
PHASE I CLINICAL TRIAL OF 17-ALLYLAMINO-17-DEMETHOXY-GELDANAMYCIN (KOS-953)
17-烯丙氨基-17-去甲氧基格尔德霉素 (KOS-953) 的 I 期临床试验
  • 批准号:
    7603888
  • 财政年份:
    2006
  • 资助金额:
    $ 0.3万
  • 项目类别:
AN OPEN-LABEL STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL SCIO-469
口服 SCIO-469 的功效、安全性和耐受性的开放标签研究
  • 批准号:
    7368175
  • 财政年份:
    2005
  • 资助金额:
    $ 0.3万
  • 项目类别:
A PILOT STUDY OF YTTRIUM-90-LABELED ANTI-CD20 MONOCLONAL
钇90标记的抗CD20单克隆抗体的初步研究
  • 批准号:
    7368164
  • 财政年份:
    2005
  • 资助金额:
    $ 0.3万
  • 项目类别:
A PILOT STUDY OF YTTRIUM-90-LABELED ANTI-CD20 MONOCLONAL
钇90标记的抗CD20单克隆抗体的初步研究
  • 批准号:
    7199962
  • 财政年份:
    2004
  • 资助金额:
    $ 0.3万
  • 项目类别:
AN OPEN-LABEL STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL SCIO-469
口服 SCIO-469 的功效、安全性和耐受性的开放标签研究
  • 批准号:
    7199978
  • 财政年份:
    2004
  • 资助金额:
    $ 0.3万
  • 项目类别:
HIGH DOSE CHEMOTHERAPY AND COMBINATION ANTI-HIV THERAPY FOR HIV ASSOCIATED HO
针对 HIV 相关性 HO 的高剂量化疗和抗 HIV 联合治疗
  • 批准号:
    7199947
  • 财政年份:
    2004
  • 资助金额:
    $ 0.3万
  • 项目类别:

相似海外基金

Defining Optimal Radiotherapy Dose and Fractionation in Combination with Preoperative Immuno-Chemotherapy in Early-Stage Triple Negative Breast Cancer
确定早期三阴性乳腺癌的最佳放疗剂量和分割与术前免疫化疗相结合
  • 批准号:
    10512391
  • 财政年份:
    2023
  • 资助金额:
    $ 0.3万
  • 项目类别:
A single-arm phase II study to evaluate the safety and efficacy of combination systematic chemotherapy and multiple rounds of endoscopic ultrasound-guided radiofrequency ablation in pancreatic cancer
评估联合系统化疗和多轮内镜超声引导射频消融治疗胰腺癌的安全性和有效性的单组 II 期研究
  • 批准号:
    10743356
  • 财政年份:
    2023
  • 资助金额:
    $ 0.3万
  • 项目类别:
Studies on effect of combination therapy with immunotherapy targeting bladder cancer stem cell-like cells and chemotherapy/radiotherapy
膀胱癌干细胞样细胞免疫疗法与化疗/放疗联合治疗的效果研究
  • 批准号:
    23K14555
  • 财政年份:
    2023
  • 资助金额:
    $ 0.3万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Novel effective combination chemotherapy using epigenetic modifiers for targeting solid tumors
使用表观遗传修饰剂靶向实体瘤的新型有效联合化疗
  • 批准号:
    21K06699
  • 财政年份:
    2021
  • 资助金额:
    $ 0.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Elucidation of synergistic mechanisms in the combination of chemotherapy and PD-1/L1 inhibitors and exploration for novel therapeutic targets
阐明化疗与PD-1/L1抑制剂联合的协同机制并探索新的治疗靶点
  • 批准号:
    21K07247
  • 财政年份:
    2021
  • 资助金额:
    $ 0.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Assessment of overcoming effect for multidrug resistance with photodynamic therapy for esophageal cancer and development of newly combination treatment with chemotherapy and photodynamic therapy
食管癌光动力治疗克服多药耐药效果评价及化疗与光动力联合治疗新方案的开发
  • 批准号:
    20K17694
  • 财政年份:
    2020
  • 资助金额:
    $ 0.3万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Immune related gene-expression profiling for the combination of chemotherapy and PD-1/PD-L1 inhibition.
化疗和 PD-1/PD-L1 抑制相结合的免疫相关基因表达谱。
  • 批准号:
    19K07785
  • 财政年份:
    2019
  • 资助金额:
    $ 0.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Low Dose Metronomic Chemotherapy as a Combination Strategy to Combat Innate or Acquired Resistance to Immune Checkpoint Therapy
低剂量节律化疗作为对抗免疫检查点治疗先天性或获得性耐药性的组合策略
  • 批准号:
    410176
  • 财政年份:
    2019
  • 资助金额:
    $ 0.3万
  • 项目类别:
    Operating Grants
The combination therapy of immuno-checkpoint inhibitor with anti NOTCH2 antibody for chemotherapy resistant bladder cancer
免疫检查点抑制剂联合抗NOTCH2抗体治疗化疗耐药膀胱癌
  • 批准号:
    19K09729
  • 财政年份:
    2019
  • 资助金额:
    $ 0.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Systems biology modeling of radiation resistance and chemotherapy-radiation combination therapies in head and neck squamous cell carcinoma
头颈鳞状细胞癌放射抗性和化疗-放射联合治疗的系统生物学模型
  • 批准号:
    10380480
  • 财政年份:
    2018
  • 资助金额:
    $ 0.3万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了